The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of feasibility study of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for clinical stage II/III esophageal squamous cell carcinoma.
H. Hara
No relevant relationships to disclose
H. Daiko
No relevant relationships to disclose
K. Kato
No relevant relationships to disclose
H. Igaki
No relevant relationships to disclose
S. Kadowaki
No relevant relationships to disclose
Y. Tanaka
No relevant relationships to disclose
Y. Hamamoto
No relevant relationships to disclose
H. Matsushita
No relevant relationships to disclose
M. Nagase
No relevant relationships to disclose
Y. Hosoya
No relevant relationships to disclose
M. Tahara
No relevant relationships to disclose